<DOC>
	<DOC>NCT02219516</DOC>
	<brief_summary>This is a Phase 1, single-dose, open-label, pharmacokinetic (PK) and pharmacodynamic (PD) study of RDEA3170 in adult male subjects with mild, moderate, and severe renal impairment.</brief_summary>
	<brief_title>Mild, Moderate and Severe Renal Impairment Study</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2. Subject with renal impairment, as determined at Screening, with creatinine clearance as calculated by the CockcroftGault formula of 60 to &lt; 90 mL/min (mild impairment), 30 to &lt; 60 mL/min (moderate impairment), or 15 to &lt; 30 mL/min (severe impairment), or a matched control subject (by age and body mass index) with a creatinine clearance of ≥ 90 mL/min. Subject has a Screening serum urate level ≥ 4.5 mg/dL and ≤ 10 mg/dL Subject has a history or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological, or psychiatric disorders. Subject has a history or suspicion of kidney stones. Subject has a history of asthma. Subject has undergone major surgery within 3 months prior to Day 1. Subject has donated blood or experienced significant blood loss (&gt; 450 mL) within 12 weeks prior to Day 1 or gave a plasma donation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>